The overall hypothesis presented in this grant provides an integrated pathophysiological schema whereby caspase-1 and caspase-1-related cytokines like IL-18 and IL-1a lead to increased macrophage and NK cell infiltration in the kidney and resultant ischemic acute renal failure (ARF). Novel published data demonstrating that impaired IL-18 processing protects caspase-1 deficient mice from ischemic ARF supports the hypothesis. Complementary studies in mice will be performed in different models: 1) ischemic ARF in vivo, 2) freshly isolated renal proximal tubules in suspension and 3) microvascular endothelial cells in culture.
In Specific Aim 1, the time course of increased caspase-1 and IL-18 expression in ischemic ARF will be determined. In addition, the therapeutic potential of newly developed caspase-1 and IL-18 inhibitors will be tested. Fractalkine is a major chemoattractant for macrophages and NK cells.
In Specific Aim 2, we shall determine whether there is a cytokine-mediated increase of fractalkine in the endothelium.
Specific Aim 3 focuses on macrophages and NK cells as sources of caspase-1, IL-18, IL-1a and other cytokines in ischemic ARF. In vivo studies using inhibitors of macrophages and NK cells will test the potential for clinical application. Activated macrophages and NK cells stimulated by IL-18 are known to mediate cell lysis via perforin and/or granzymes.
In Specific Aim 4, we propose that IL-18-dependent or independent production of perforin and gzmA by macrophages and NK cells contributes to FT injury (in vitro) and ATN (in vivo). The relevance of these studies to clinical ARF is substantial. The results should provide new insights into the pathophysiology of ischemic ARF as well as leads to altering the course of ischemic ARF. This is particularly true because of the current availability of caspase-1 and IL-18 inhibitors e.g. pralnacasan and IL-18 binding protein (IL-18 BP) that are being tested in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK056851-09
Application #
7798944
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Kimmel, Paul
Project Start
1999-12-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2012-03-31
Support Year
9
Fiscal Year
2010
Total Cost
$289,640
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Kim, Hyun-Jung; Lee, Dong Won; Ravichandran, Kameswaran et al. (2013) NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther 346:465-72
Huber, Tobias B; Edelstein, Charles L; Hartleben, Bjorn et al. (2012) Emerging role of autophagy in kidney function, diseases and aging. Autophagy 8:1009-31
Andres-Hernando, Ana; Dursun, Belda; Altmann, Christopher et al. (2012) Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy. Nephrol Dial Transplant 27:4339-47
Lu, Lawrence; Faubel, Sarah; He, Zhibin et al. (2012) Depletion of macrophages and dendritic cells in ischemic acute kidney injury. Am J Nephrol 35:181-90
Turkmen, Kultigin; Martin, Jessica; Akcay, Ali et al. (2011) Apoptosis and autophagy in cold preservation ischemia. Transplantation 91:1192-7
Jani, Alkesh; Zimmerman, Michael; Martin, Jessica et al. (2011) Perfusion storage reduces apoptosis in a porcine kidney model of donation after cardiac death. Transplantation 91:169-75
Jani, Alkesh; Epperson, Elaine; Martin, Jessica et al. (2011) Renal protection from prolonged cold ischemia and warm reperfusion in hibernating squirrels. Transplantation 92:1215-21
Lee, D W; Faubel, S; Edelstein, C L (2011) Cytokines in acute kidney injury (AKI). Clin Nephrol 76:165-73
Akcay, Ali; Nguyen, Quocan; He, Zhibin et al. (2011) IL-33 exacerbates acute kidney injury. J Am Soc Nephrol 22:2057-67
Belibi, Franck A; Edelstein, Charles L (2010) Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs 19:315-28

Showing the most recent 10 out of 40 publications